Latest

Anti-CD19

Home Anti-CD19

Anti-CD19

Chinese Research Reveals Sequential Infusion of Humanized CD19-Modified & CD22-modified CAR-T...

March 26, 2019

CRO Parexel Applies Its Patient Centric Protocol Optimization Process in China

June 19, 2019

Did VC Third Rock Conspire with BlueBird Bio to Hurt Errant Gene Therapeutics?

June 19, 2019

Ludwig Cancer Research Identify Biomarkers for Potential Cancer Immunotherapy

June 19, 2019

Harvard Breakthrough Anti-Cancer Agent E7130 Nearing Clinicals

June 19, 2019

TrialSite News is the only digital media dedicated 100% to transparent and open coverage of clinical research trial sites around the globe. Based in the Silicon Slopes in downtown Salt Lake City, Utah, we are founded by a team of experts in the clinical trials industry and dedicated to transparency, quality and clinical trial innovation.

159 West Broadway Suite 200
Salt Lake City, UT 84101
Contact us: admin@trialsitenews.com

Privacy Policy

Contact

© TrialSite News, Inc. All Rights Reserved

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok

Edit with Live CSS

Save
Write CSS OR LESS and hit save. CTRL + SPACE for auto-complete.

Chinese Research Reveals Sequential Infusion of Humanized CD19-Modified & CD22-modified CAR-T...

EDITOR PICKS

CRO Parexel Applies Its Patient Centric Protocol Optimization Process in China

Did VC Third Rock Conspire with BlueBird Bio to Hurt Errant Gene Therapeutics?

Ludwig Cancer Research Identify Biomarkers for Potential Cancer Immunotherapy

Harvard Breakthrough Anti-Cancer Agent E7130 Nearing Clinicals